📰 William Bonello News
Page 2 - William Bonello News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from William Bonello. Real-time updates on events, politics, business and more.
April 12, 2022
Equities analysts expect NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) to post earnings per share (EPS) of ($0.19) for the current quarter, according to Zacks. Four analysts have provided estimates for NeoGenomics’ earnings, with estimates ranging from ($0.27) to ($0.10). NeoGenomics reported earnings per share of ($0.04) in the same quarter last year, which suggests a […]
April 7, 2022
National Bank of Canada FI acquired a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) during the 4th quarter, Holdings Channel.com reports. The firm acquired 3,700 shares of the medical research company’s stock, valued at approximately $126,000. A number of other institutional investors have also modified their holdings of NEO. Thrivent Financial […]
April 5, 2022
Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) have received an average recommendation of “Hold” from the thirteen brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The average […]
April 2, 2022
NeoGenomics (NASDAQ:NEO – Get Rating) had its price objective cut by Benchmark from $26.00 to $16.00 in a research report sent to investors on Tuesday, The Fly reports. A number of other research firms have also recently issued reports on NEO. SVB Leerink cut their price objective on NeoGenomics from $45.00 to $20.00 and set […]
April 1, 2022
NeoGenomics (NASDAQ:NEO – Get Rating) had its price objective trimmed by Needham & Company LLC from $29.00 to $19.00 in a report issued on Tuesday, The Fly reports. The firm currently has a buy rating on the medical research company’s stock. Other research analysts also recently issued research reports about the company. SVB Leerink reduced […]
April 1, 2022
NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) – Research analysts at SVB Leerink cut their Q1 2022 EPS estimates for shares of NeoGenomics in a note issued to investors on Monday, March 28th. SVB Leerink analyst P. Souda now anticipates that the medical research company will earn ($0.31) per share for the quarter, down from their […]
April 1, 2022
Shares of NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) saw an uptick in trading volume on Wednesday . 86,674 shares changed hands during trading, a decline of 93% from the previous session’s volume of 1,174,509 shares.The stock last traded at $12.88 and had previously closed at $12.49. A number of research firms recently commented on NEO. […]
March 30, 2022
Stephens lowered shares of NeoGenomics (NASDAQ:NEO – Get Rating) from an overweight rating to an equal weight rating in a research note issued to investors on Tuesday, Marketbeat.com reports. Stephens currently has $16.00 target price on the medical research company’s stock, down from their prior target price of $34.00. A number of other equities research […]
March 30, 2022
NeoGenomics (NASDAQ:NEO – Get Rating) had its price objective lowered by SVB Leerink from $45.00 to $20.00 in a research report released on Tuesday, The Fly reports. The firm currently has an outperform rating on the medical research company’s stock. Several other equities research analysts have also weighed in on the stock. Raymond James cut […]
March 29, 2022
Fort Myers-based cancer-focused testing and research lab NeoGenomics announced Mark Mallon, who had been CEO for less than a year, has stepped down.